drugset / Trial / NCT00326209

Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission

NCT00326209

Phase 3 Completed 393 enrolled Bausch Health Americas, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the long-term safety and tolerability of encapsulated mesalamine Granules (eMG) (formerly referred to as Mesalamine Pellets \[MP\]) in participants with ulcerative colitis currently in remission.

Timeline

Start
2005-12-22
Primary completion
2008-05-05
Completion
2008-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 1.5 g Oral

Indications